Mirum Pharmaceuticals said its Phase 3 AZURE-4 study for brelovitug reached an important goal.

Nov 10, 2026, 7:52 AM ETTrialRead the original at SEC EDGAR

Good for MIRM

Mirum's brelovitug met the main goal in its second Phase 3 study, supporting the company's planned U.S. filing. The drug still needs FDA approval, so a launch is not assured.

MIRM · Mirum Pharmaceuticals, Inc.

AI read · Good for MIRM

The AI's read

This gives Mirum stronger support for seeking U.S. approval, since AZURE-4 is the second of two Phase 3 studies planned for its filing. The study also reported no new safety signals. Brelovitug is still experimental, and Mirum needs FDA approval before it can sell the drug.

Get alerts for MIRM

Follow Mirum Pharmaceuticals, Inc. (MIRM) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for MIRM

Free on the App Store and Google Play, or on the web.